Feed BHVN
BH

Biohaven

BHVN · NYSE

$13.61 -2.05% (-$0.29)
1M +2.89%
Market Cap $1.92B
P/E Ratio -
Div. Yield -
ROE 1,328.94%

Bulios Fair Price

$12.1

11.1% downside

Trenutna cena

$13.61

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BHVN trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 157.31x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 54.11%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROE 1,328.94%
ROA 158.29%
Asset turnover 0.00x
Debt
33 /100
High
Current ratio 4.73x
Debt/Equity 24.30x
Net debt/EBITDA N/A
Stability
11 /100
Unstable
EPS volatility 60.94%
Profitable years 0
Beta 3.17x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BHVN
Online

O podjetju

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is a biotechnology company focused on researching, developing, and commercializing therapeutic products for the treatment of neurological and psychiatric disorders. The company aims to discover novel drug candidates and innovative therapies for patients suffering from migraine, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders. Biohaven is advancing and testing drugs in various stages of clinical trials and aspires to bring new therapeutic solutions to the field of neurological treatment. The company collaborates with academic and industry partners and focuses on innovation in the field of neuroscience. Biohaven Pharmaceutical Holding Company Ltd. (BHVN) shares may present an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with promising neurological treatment innovations and a strong commitment to addressing neurological disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Vladimir Coric

Employees

274

Headquarters

New Haven

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

51d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.